If your email program has trouble displaying this email, view as a webpage. Recently Posted Guidance Documents 5/27/2021 - Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Industry and Food and Drug Administration Staff 5/27/2021 - Procedures for Handling Post-Approval Studies Imposed by Premarket Approval Application Order: Draft Guidance for Industry and Food and Drug Administration Staff 5/26/2021 - Tobacco Product User Fees: Responses to Frequently Asked Questions 5/25/2021 - Emergency Use Authorization for Vaccines to Prevent COVID-19: Guidance for Industry 5/24/2021 - Bispecific Antibody Development Programs Guidance for Industry 5/24/2021 - FDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs: Amendments to Sec. 505B of the FD&C Act: Guidance for Industry Guidance Document Search Search all FDA official guidance documents and other regulatory guidance

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA